JNJ vs PDEX

Johnson & Johnson (JNJ) remains a fundamentally strong, diversified healthcare conglomerate with an impressive market capitalization. While possessing robust financials, wide economic moats, and consistent performance, its sheer size ($579.46B) fundamentally misaligns with the criteria for 10x growth within a 3-5 year timeframe. A 10x return would necessitate a market cap exceeding $5.7 trillion, ...

Pro-Dex Inc. remains a financially robust and profitable specialized contract manufacturer, characterized by a strong balance sheet and stable profitability (TTM revenue $66.59M, net income $8.98M, TTM P/E ~20.16 based on current price and EPS). Fiscal 2025 revenue grew 23.68% YoY. However, its fundamental business model, while essential and reliable, does not exhibit the disruptive innovation, ex...